Detection of circulating tumour cells with a hybrid (epithelial/ mesenchymal) phenotype in patients with metastatic non-small cell lung cancerLECHARPENTIER, A; VIELH, P; PEREZ-MORENO, P et al.British journal of cancer. 2011, Vol 105, Num 9, pp 1338-1341, issn 0007-0920, 4 p.Article

Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)BALDINI, Editta; ARDIZZONI, Andrea; PROCHILO, Tiziana et al.Cancer chemotherapy and pharmacology. 2002, Vol 49, pp S25-S28, issn 0344-5704, SUP1Conference Paper

EGFR and KRAS mutations in metastatic lung adenocarcinomasMUNFUS-MCCRAY, Delicia; HARADA, Shuko; ADAMS, Christina et al.Human pathology. 2011, Vol 42, Num 10, pp 1447-1453, issn 0046-8177, 7 p.Article

Erlotinib for Metastatic Non-Small-Cell Lung Cancer : First-, Second-or Third-Line Setting -Does It Matter ? A Single-Institution ExperienceAILAWADHI, Sikander; DERBY, Lyudmyla; NATARAJAN, Raj et al.Oncology. 2009, Vol 76, Num 2, pp 85-90, issn 0030-2414, 6 p.Article

Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancerJUHASZ, Erzsebet; KIM, Joo-Hang; KLINGELSCHMITT, Gaelle et al.European journal of cancer (1990). 2013, Vol 49, Num 6, pp 1205-1215, issn 0959-8049, 11 p.Article